Xenomics Closes US$1.0 Million Financing

New York (ots/PRNewswire) -

Xenomics, Inc. (the "Company") (OTC Bulletin Board: XNOM; FWB:
XE7), source of next-generation medical DNA technologies, announced
today the closing of a private placement totaling US$1.0 million,
whose proceeds will help to fund the Company's efforts to develop
advanced medical diagnostic tests for a range of diseases and genetic
conditions, and to fund preparations toward product regulatory
approval and commercialization.

The Company placed 1,000,000 shares of common stock and 500,000
warrants (the "Warrants") to an overseas institutional investor for
aggregate gross proceeds of US$1,000,000. The Warrants are
immediately exercisable for a period of six (6) months from the date
of issuance at US$1.25 per share.

The securities issued in the private placement have not been
registered under the Securities Act of 1933, as amended. Accordingly,
these securities may not be offered or sold in the United States,
except pursuant to the effectiveness of a registration statement or
an applicable exemption from the registration requirements of the
Securities Act. The Company has agreed to file a registration
statement covering resale of the shares of common stock underlying
the warrants by the private placement investor. This press release
shall not constitute an offer to sell or the solicitation of an offer
to buy the securities.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the
development of DNA-based tests using transrenal DNA. Xenomics'
patented technology uses safe and simple urine collection and can be
applied to a broad range of applications, including detection and
monitoring of infectious diseases, tumor detection and therapeutic
monitoring, stem cell transplantation monitoring, and prenatal
genetic testing.

Scientists from Xenomics were the first to report that fragments
of DNA from cells can cross the kidney barrier and be readily
detected in small urine specimens. The company believes that its
transrenal DNA technology will open significant new markets in the
molecular diagnostics field and provide a new generation of molecular
diagnostic tests. Xenomics' issued U.S. patents protect an array of
applications for molecular diagnostics and genetic testing.

Xenomics' stock trades under the symbol XNOM.OB and is also listed
on the Frankfurt Stock Exchange under the symbol XE7.

For additional information, please visit www.xenomics.com .

Forward-Looking Statements

Certain statements made in this press release are forward looking.
Such statements are indicated by words such as "expect," "might,"
"should," "anticipate" and similar words indicating uncertainty in
facts and figures. Although Xenomics believes that the expectations
reflected in such forward-looking statements are reasonable, it can
give no assurance that such expectations reflected in such
forward-looking statements will prove to be correct. As discussed in
Xenomics' Form 10-KSB as filed with the Securities and Exchange
Commission on May 16, 2006, actual results could differ materially
from those projected in the forward-looking statements as a result of
the following factors, among others: uncertainties associated with
product development, the risk that Xenomics will not obtain approval
to market its products, the risk that Xenomics' technology will not
gain market acceptance, the risks associated with dependence upon key
personnel, and the need for additional financing.

Contact:
Xenomics Investor Relations
+1-212-297-0808 Option 1
www.xenomics.com

Web site: http://www.xenomics.com

ots Originaltext: Xenomics, Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Xenomics Investor Relations, +1-212-297-0808 Option 1